Association of pre-hospital theophylline use and mortality in chronic obstructive pulmonary disease patients with sepsis. (April 2017)

• Record Type: Journal Article
• Authors: Shih, Yu-Ning; Chen, Yung-Tai; Chu, Hsi; Shih, Chia-Jen; Ou, Shuo-Ming; Hsu, Yen-Tao; Chen, Ran-Chou; Quraishi, Sadeq A.; Aisiku, Imoigele P.; Seethala, Raghu R.; Frendl, Gyorgy; Hou, Peter C.
• Is Part Of: Respiratory medicine. Volume 125(2017)
• Page Start: 33
• Page End: 38
• Publication Date: 2017-04
• Subjects: Theophylline -- Sepsis -- COPD -- Mortality; Chest -- Diseases -- Periodicals; Chest -- Diseases -- Great Britain -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Appareil respiratoire -- Maladies -- Périodiques; Thorax -- Maladies -- Périodiques; Appareil respiratoire -- Maladies -- Traitement -- Périodiques; Electronic journals; 616.2
• DOI: 10.1016/j.rmed.2017.02.020
• Languages: English
• ISSNs: 0954-6111

Abstract

Abstract: Background: Although theophylline has been shown to have anti-inflammatory effects, the therapeutic use of theophylline before sepsis is unknown. The aim of our study was to determine the effect of theophylline on COPD patients presenting with sepsis. Methods: This nationwide, population-based, propensity score-matched analysis used data from the linked administrative databases of Taiwan's National Health Insurance program. Patients with COPD who were hospitalized for sepsis between 2000 and 2011 were divided into theophylline users and non-users. The primary outcome was 30-day mortality. The secondary outcome was in-hospital death, intensive care unit admission, and need for mechanical ventilation. Cox proportional hazard model and conditional logistic regression were used to calculate the risk between groups. Results: A propensity score-matched cohort of 51, 801 theophylline users and 51, 801 non-users was included. Compared with non-users, the 30-day (HR 0.931, 95% CI 0.910–0.953), 180-day (HR 0.930, 95% CI 0.914–0.946), 365-day (HR 0.944, 95% CI 0.929–0.960) and overall mortality (HR 0.965, 95% CI 0.952–0.979) were all significantly lower in theophylline users. Additionally, the theophylline users also had lower risk of in-hospital death (OR 0.895, 95% CI 0.873–0.918) and need for mechanical ventilation (OR 0.972, 95% CI 0.949–0.997). Conclusions: Theophylline use is associated with a lower risk of sepsis-related mortality in COPD patients. Pre-hospital theophylline use may be protective to COPD patients with sepsis. Highlights: Theophylline has been shown to have anti-inflammatory effects at low concentrations. Theophylline may be a potential therapeutic agent in the treatment of sepsis. Theophylline use is associated with a lower risk of sepsis-related mortality in COPD patients. Pre-hospital theophylline use may be protective to COPD patients with sepsis.